logo-loader

MaxCyte starts dosing second cohort of patients in early-stage trial of its lead cancer drug

Published: 07:25 08 May 2019 BST

ovarian cancer
MCY-M11 has been developed from MaxCyte’s own CARMA cell therapy platform

MaxCyte Inc (LON:MXCT) has started dosing the second cohort of patients in the phase I clinical trial of its MCY-M11 cancer immunotherapy.

MCY-M11 is the first drug from MaxCyte’s CARMA cell therapy platform. It is being used to treat 15 women with ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.

READ: MaxCyte shows off CARMA platform at Washington DC conference

The women in this second cohort will receive a higher dose of the drug than those who were part of the first wave of patients.

There were no dose-limiting toxicities or safety concerns observed in the first set of cancer sufferers, MaxCyte confirmed.

“Successfully completing patient dosing in our first cohort and initiating dosing in a second higher-dose cohort are important milestones for MaxCyte, representing tangible progress for our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform,” said chief medical officer Claudio Dansky Ullmann.

“We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumours where the majority of patients still have very limited treatment options.”

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

15 minutes ago